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PLINICAL RESEARCH Clinical Trials
ong-Term Results (Three to Five Years)
f the Restenosis Intrastent: Balloon Angioplasty
ersus Elective Stenting (RIBS) Randomized Study
ernando Alfonso, MD,* José M. Augé, MD,†§§ Javier Zueco, MD,‡ Armando Bethencourt, MD,§
osé R. López-Mínguez, MD, José M. Hernández, MD,¶ Juan A. Bullones, MD,# Isabel Calvo, MD,**
nrique Esplugas, MD,†† María J. Pérez-Vizcayno, MD,* Raul Moreno, MD,* Cristina Fernández, MD,*
osana Hernández, MD,* Vasco Gama-Ribeiro, MD,‡‡ for the RIBS Investigators
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OBJECTIVES We sought to analyze the very late outcomes of patients treated for in-stent restenosis (ISR)
according to treatment allocation and 10 prespecified variables.
BACKGROUND Long-term results (2 years) of patients with ISR undergoing repeat coronary interventions
are not well established.
METHODS The Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized
study compared these two strategies in 450 patients with ISR. A detailed systematic protocol
was used for late clinical follow-up.
RESULTS At one-year follow-up (100% of patients), the event-free survival was similar in the two
groups (77% stent implantation [ST] arm, 71% balloon angioplasty [BA] arm, log-rank p 
0.19). Additional long-term clinical follow-up (median 4.3 years, range 3 to 5 years) was
obtained in 98.6% of patients. During this time 22 additional patients died (9 ST arm, 13 BA
arm), 7 suffered a myocardial infarction (3 ST arm, 4 BA arm), 23 required coronary surgery
(11 ST arm, 12 BA arm), and 9 underwent repeat coronary interventions (4 ST arm, 5 BA
arm) (nonexclusive events). At four years the event-free survival was 69% in the ST arm and
64% in the BA arm (log-rank p  0.21). Among the 10 prespecified variables, vessel size 3
mm had a major influence on the clinical outcome at four years, with better results in the ST
group (hazard ratio 0.51, 95% confidence interval 0.3 to 0.89, p  0.016).
CONCLUSIONS Patients with ISR undergoing repeat interventions have a significant event rate at late
follow-up. Continued medical surveillance should be continued after one year. Patients with
large vessels have a better outcome after repeat stenting. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.050756–60) © 2005 by the American College of Cardiology Foundation
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poronary stenting currently represents the default strategy
uring percutaneous coronary interventions (PCI) (1,2).
n-stent restenosis (ISR), however, remains the major lim-
tation of this therapy (1–10). Although several mechanical
trategies have been proposed in patients with ISR (3–9),
everal randomized trials have failed to confirm initial
xpectations (7–9). Brachytherapy is highly effective in these
atients, but technical and logistic drawbacks limit its use
11). Drug-eluting stents represent a major therapeutic
reakthrough (2,12,13), but larger studies are required
efore the systematic use of these new devices is justified in
ll patients with ISR.
Accordingly, there is still a need to gain further insights
n the long-term outcome of patients with ISR undergoing
epeat PCI. In the Restenosis Intrastent: Balloon angio-
From the University Hospitals: *Clinico San Carlos, Madrid, Spain; †Santa Cruz
San Pablo, Barcelona, Spain; ‡Marqués de Valdecilla, Santander, Spain; §Son
ureta, Palma de Mallorca, Spain; Infanta-Cristina, Badajoz, Spain; ¶Virgen de la
ictoria, Malaga, Spain; #Carlos Haya, Malaga, Spain; **Miguel Servet, Zaragoza,
pain; ††Bellvitge, Barcelona, Spain; and ‡‡Vila Nova de Gaia, Porto, Portugal.
§Deceased.o
Manuscript received January 7, 2005; revised manuscript received April 25, 2005,
ccepted May 9, 2005.lasty versus elective Stenting (RIBS) randomized study,
50 patients with ISR were randomized. The acute and
id-term results of this study have been previously reported
8). The present report describes the long-term (three to five
ears) clinical outcome of these patients. In addition, we
ought to evaluate the influence of 10 “predefined” relevant
ariables on long-term prognosis.
ETHODS
atients and protocol. The protocol and primary end
oint of the RIBS trial have been reported (8). Patients with
yocardial ischemia and ISR lesions 32 mm in length in
essels 2.5 mm were eligible. Twenty-four sites from
pain and Portugal participated in the trial. All patients
eceived aspirin, and those undergoing repeat stenting also
eceived ticlopidine for one month. Patients were
ollowed-up at 1, 7, and 12 months. Late angiographic
ollow-up was obtained in 96% of eligible patients (8).
hen complete one-year results were available, all partici-
ating centers agreed to maintain a close clinical follow-up
f these patients. Accordingly, the same detailed standard-
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September 6, 2005:756–60 Late Outcome for ISRzed forms were forwarded to the coordinating center yearly
hereafter. Queries about missing or inconsistent data were
ent back to the sites. Summaries of clinical records from all
atients with potential events were reviewed. Eventually, all
vents were classified and adjudicated by an independent
linical events committee unaware of the assigned
reatment.
Death was considered as cardiac unless a noncardiac cause
ould be demonstrated. Differentiation between cardiac/
oncardiac death was predefined in the protocol. Myocar-
ial infarction (MI) required two of the following: pro-
onged (30 min) chest pain, new Q waves, and creatine
inase levels 2 of the upper normal value (with MB
raction 10% of total). The composite of death, MI, and
arget vessel revascularization was a prespecified secondary
tudy end point.
Abbreviations and Acronyms
BA  balloon angioplasty
ISR  in-stent restenosis
MI  myocardial infarction
PCI  percutaneous coronary intervention
RIBS  Restenosis Intrastent: Balloon angioplasty versus
elective Stenting randomized study
ST  stent implantation
Table 1. Events at Early and Long-Term Clin
Events
Stent
(n  224
Hospital events, n (%)
Death 1 (0.4)
Myocardial infarction 2 (0.9)
Target vessel revascularization 1 (0.4)
Coronary angioplasty 1 (0.4)
Coronary surgery 0 (0)
Any major hospital event 3 (1.3)
Events at 7 months, n (%)
Death 5 (2.2)
Myocardial infarction 5 (2.2)
Target vessel revascularization 37 (16.5)
Coronary angioplasty 27 (12)
Coronary surgery 12 (5.4)
Any major event at 7 months 42 (19)
Events at 1 yr, n (%)
Death 8 (4)
Myocardial infarction 6 (2.7)
Target vessel revascularization 44 (19.6)
Coronary angioplasty 32 (14)
Coronary surgery 14 (6.3)
Any major event at 1 yr 52 (23)
Events at last follow-up, n (%) (n  223
Death 17 (8)
Myocardial infarction 9 (4)
Target vessel revascularization 55 (25)
Coronary angioplasty 36 (16)
Coronary surgery 25 (11)
Any major event at last follow-up 70 (31)
Patients with more than one event are counted only once f
separately in the corresponding category.
CI  confidence interval (p values from Cox analysis); HR tatistical analysis. Kaplan-Meier curves were constructed
o estimate event-free survival. Event-rates were compared
ith the log-rank test. Cox proportional hazard analyses
ere used to determine long-term outcome. Hazard ratios
ere calculated for the 10 relevant prespecified variables (8).
ll analyses were performed according to the intention-to-
reat principle, using the SPSS package (version 12.0, SPSS
nc., Chicago, Illinois). A p value 0.05 was considered
tatistically significant.
ESULTS
ne year clinical follow-up was obtained in all 450 patients
100%). A clinical follow-up 1 year was obtained in 445
atients (98.8%); a follow-up 3 years was obtained in 444
atients (98.6%) (223 stent implantation [ST] arm, 221
alloon angioplasty [BA] arm). The last clinical follow-up
as obtained at 4.3 years (mean 1,537  260 days; median
,569 days [interquartile range 1,362 to 1,736 days]). Table
summarizes clinical events (as total counts) during the
omplete follow-up period. A total of 52 patients (12%)
xperienced at least one adverse event after the first year of
ollow-up (including 36 patients that did not have an
dverse event during the first year). When all events
ccurring after the first year were analyzed (nonexclusive
vents), 22 patients died (9 ST arm, 13 BA arm), 7 suffered
ollow-Up
Balloon
(n  226) p Value HR (95% CI)
1 (0.4) 1 1 (0.06–16.03)
9 (4) 0.06 0.22 (0.05–1.03)
2 (0.9) 1 0.50 (0.046–5.52)
1 (0.4) 1 1 (0.06–16.03)
1 (0.4)
11 (4.9) 0.039 0.27 (0.078–0.97)
4 (1.8) 0.75 1.26 (0.34–4.64)
12 (5.3) 0.13 0.42 (0.15–1.17)
39 (17.3) 0.9 0.96 (0.63–1.44)
29 (12.8) 0.89 0.94 (0.57–1.53)
11 (4.9) 0.83 1.10 (0.49–2.44)
47 (21) 0.64 0.90 (0.62–1.31)
7 (3) 0.8 1.15 (0.42–3.12)
13 (5.8) 0.15 0.46 (0.18–1.20)
55 (24.3) 0.25 0.81 (0.57–1.14)
43 (19) 0.20 0.75 (0.49–1.14)
13 (5.8) 0.84 1.08 (0.52–2.26)
65 (29) 0.19 0.81 (0.58–1.10)
(n  221)
20 (9) 0.61 0.85 (0.44–1.62)
17 (8) 0.10 0.52 (0.23–1.17)
65 (29) 0.35 0.84 (0.59–1.21)
47 (21) 0.24 0.77 (0.50–1.19)
25 (11) 0.98 0.99 (0.57–1.73)
83 (37) 0.21 0.82 (0.60–1.12)
composite clinical end points although each event is listedical F
)
)
or thehazard risk (stent vs. balloon).
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Late Outcome for ISR September 6, 2005:756–60MI (3 ST arm, 4 BA arm), 23 required coronary surgery
11 ST arm, 12 BA arm), and 9 underwent repeat PCI (4
T arm, 5 BA arm). Of the 32 patients requiring “late”
arget vessel revascularization, 11 patients had documented
estenosis at 6 months (initially left untreated due to a lack
f symptoms), 10 developed “late restenosis,” and 11 had
epeated procedures. Ranked by hierarchy (exclusive events),
2 patients died (9 ST arm, 13 BA arm), 5 suffered a MI (2
T arm, 3 BA arm), 18 required surgical revascularization
10 ST arm, 8 BA arm), and 7 required repeat PCI (3 ST
rm, 4 BA arm) after the first year.
At last clinical follow-up, a total of 37 patients had died
17 ST arm, 20 BA arm), 16 had suffered a MI (6 ST arm,
0 BA arm), 38 had required surgery (20 ST arm, 18 BA
rm), and 62 patients had required repeat PCI (27 ST arm,
5 BA arm) (hierarchical ranking). Death was cardiac in 20
ases (6 ST arm, 14 BA arm, p  0.07), and 10 of these
atients died after the first year (1 ST arm, 9 BA arm, p 
.02). Only two cardiac deaths were sudden (one patient in
ach group). Angiographically demonstrated abrupt vessel
losure associated with an acute coronary syndrome was
nly seen in one patient in each group (both during the first
ear of follow-up).
Figure 1 displays the event-free survival according to
reatment allocation. A nonsignificant trend favoring repeat
igure 1. Event-free survival (EFS) at four years. (A) Freedom from deat
cardiac” death, myocardial infarction, and target vessel revascularization. (C) F
arget vessel revascularization.tenting was found for the combined clinical end point. In
ddition, a significant reduction in the occurrence of cardiac
eath/MI (end point not prespecified) was demonstrated
fter restenting. Cox analysis of the long-term clinical
utcome according to the 10 prespecified variables is shown
n Figure 2. Most subgroups showed results consistent with
he main outcome measure except for patients with large
essels that presented a significantly better outcome after
epeat stenting (hazard ratio 0.51, 95% confidence interval
.30 to 0.89, p  0.016). Patients with diffuse ISR (Cox,
 0.07) and those with lesions in the right or circumflex
oronary arteries (Cox, p 0.02) also had a better prognosis
fter repeat stenting (Fig. 2). However, an interaction was
ound between vessel size and these two variables. The
eference vessel diameter was significantly larger in patients
ith diffuse restenosis (2.94  0.5 mm vs. 2.79  0.5 mm,
 0.001) and in non-left anterior descending coronary
rtery lesions (2.97  0.5 mm vs. 2.74  0.4 mm, p 
.001).
Event-free survival for patients with large vessels is
epicted in Figure 3. The better long-term results obtained
ith repeat stenting were largely driven by a lesser require-
ent for target vessel revascularization (16% vs. 35%; Cox,
 0.016).
ocardial infarction, and target vessel revascularization. (B) Freedom fromh, my
reedom from “cardiac” death or myocardial infarction. (D) Freedom from
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September 6, 2005:756–60 Late Outcome for ISRISCUSSION
his study constitutes the longest and most exhaustive
linical follow-up of a large cohort of patients with ISR
ndergoing repeat PCI. Our follow-up protocol enabled us
o obtain a uniquely high rate of late clinical information. In
he RIBS study, most adverse events clustered during the
rst year of follow-up. Although the systematic late angio-
raphic follow-up could have influenced the rate of subse-
uent target vessel revascularization (14), by protocol all
epeated revascularizations needed to be clinically driven
symptoms or evidence of ischemia). Accordingly, in some
atients with recurrent ISR, the procedure was deferred
ntil ischemia could be demonstrated. This could explain
he relatively high attrition rate noticed from the sixth
onth to the end of the first year of follow-up. After this
ime the rate of new events was markedly reduced, but still
significant number of patients suffer from new events.
revious studies. No previous study has systematically
nalyzed the late clinical outcome of patients with ISR
ndergoing repeated mechanical PCI after two years of
ollow-up. Reimers et al. (3) reported an event-free survival
f 81% at 24 months (mean follow-up 27  15 months) in
igure 2. Clinical events according to the 10 prespecified variables. B/A 
alloon-to-artery ratio; CI  confidence interval; LAD  left anterior
escending coronary artery; RE  restenosis.24 patients with ISR. Bossi et al. (5) followed-up (median
v
m59 days) 234 ISR patients treated with balloon angioplasty
nd found an event-free survival of 75% at 24 months.
inally, in the meta-analysis of Radke et al. (10) (3,012 ISR
atients from 28 studies), the estimated probability of
xperiencing a major adverse event (mean follow-up 9  4
onths) was 30%. The rate of adverse events was compa-
able among different treatment modalities, and the post-
rocedural diameter stenosis was the only independent
redictor of long-term outcome. Recent data from three
arge randomized trials confirm these findings demonstrat-
ng comparable clinical results at one year, irrespective of the
echanical strategy selected (balloon, rotational atherec-
omy, cutting balloon, or restenting) (7–9).
Conversely, the late outcome of selected patients with
SR undergoing brachytherapy has been examined in detail.
he concerns of a potential late “catch-up” phenomenon
delaying rather than preventing restenosis) stimulated
onger follow-up studies in small patient subsets. A delayed
itigation of efficacy, associated with a need for late target
essel revascularization, was demonstrated in some irradi-
ted patients (11). The lifespan of this technology, however,
s currently seriously threatened in the era of drug-eluting
tents.
resent study. Our findings suggest that most patients
reated for ISR have a good long-term outcome, but 34% of
atients experience at least one adverse event at 4.3 years of
ollow-up. In addition, our data also indicate the impor-
ance of maintaining an adequate clinical follow-up after the
rst year, considering that some patients (up to 12%) will
xperience very late adverse events. It should be kept in
ind that most patients included in our trial had complex
nd advanced coronary artery disease (27% diabetics, 43%
revious MI, 45% multivessel disease) (8). These factors and
n overall recurrent restenosis rate of 38% (8) could explain
he relatively high rates of coronary surgery and mortality at
ate follow-up.
Interestingly, we found a trend, which did not reach
tatistical significance, toward a better outcome after repeat
tenting in all analyzed clinical outcome measures that
merged in the early period. Although cardiac death and the
igure 3. Event-free survival (EFS) (death, myocardial infarction, target
essel revascularization) in patients with large vessels according to treat-
ent allocation.
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Late Outcome for ISR September 6, 2005:756–60ombined end point of cardiac death/MI at late follow-up
ere significantly lower after repeat stenting, these findings
hould be interpreted with caution because they come from
ost-hoc analyses, and the study design was underpowered
o address this issue.
Our findings are particularly relevant for patients under-
oing repeat stenting because long-term data in this
cenario is very limited (8). Furthermore, this informa-
ion is also of interest considering that currently most
enters are using drug-eluting stents as the workhorse
trategy for patients with ISR. Once the benefit of the
rug coating is obtained, our results, demonstrating that
he presence of two layers of metal on the vessel wall is
ot associated with any adverse long-term implication,
re particularly reassuring.
Another important finding of the current study is that
atients with ISR in large vessels do much better after
epeat stenting than after balloon angioplasty, and this
mproved clinical outcome is maintained after 4.3 years.
herefore, the present report confirms our initial findings
8) in this important prespecified patient subset. The better
utcome after restenting for patients with diffuse ISR and
SR in locations other than the left anterior descending
oronary artery are also noteworthy. However, these two
natomic scenarios were associated with larger vessels, and
heir clinical implications remain difficult to establish. Fi-
ally, some patient subsets (small vessels, focal, left anterior
escending coronary artery, and early ISR) do not appear to
ain additional clinical benefit from repeat stenting.
tudy limitations. Only bare-metal stents were used in the
IBS study. The mid-term results of drug-eluting stents in
his setting are excellent (12,13), but long-term information
s eagerly awaited. Because intravascular ultrasound was not
ystematically performed, its potential implications on long-
erm outcome were not analyzed. Medical treatment at one
ear (statins 48%, beta-blockers 63%, and angiotensin-
onverting enzyme inhibitors 44%) was well balanced in the
wo groups. However, the potential influence of medical
reatment on clinical outcome after this time cannot be
stablished from our study.
onclusions. Patients with ISR undergoing repeat PCI
ave a significant rate of adverse events at late follow-up.
lthough most events tend to concentrate during the initial
ear, a low but steady rate of adverse events occur later on.
ccordingly, continued clinical surveillance appears war-
anted in these patients. Finally, the long-term clinical
utcome of patients with ISR in large vessels treated with
epeat stenting is favorable. teprint requests and correspondence: Dr. Fernando Alfonso, Car-
iología Intervencionista, Hospital Universitario “San Carlos,” Plaza
e Cristo Rey, Madrid 28040, Spain. E-mail: falf@hotmail.com.
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or a list of the RIBS Investigators and institutions that
articipated in this study, please see the online version of
his article.
